Pda | Technical Report 82

The primary goal of TR-82 is to provide a science-based framework for:

The report focuses on parenteral drug products (solutions, suspensions, emulsions) and medical devices, particularly those containing surfactants, preservatives, chelators, or lipids—formulations known to mask endotoxin activity.

TR 82 is structured to guide a manufacturer from basic theory to actionable practice. Below is a breakdown of its seven major sections. pda technical report 82

PDA TR-82 (2018) addresses a critical and often misunderstood analytical phenomenon in pharmaceutical quality control: Low Endotoxin Recovery (LER). LER refers to the situation where endotoxin activity is detectable immediately after spiking a sample but becomes significantly reduced or undetectable after storage, even though the endotoxin is physically present. This creates a dangerous false sense of security, as a product might pass the endotoxin test (BET) while still harboring potentially pyrogenic contaminants.

This is the most operationally critical section of TR 82. The report suggests that standard BET validation (per USP <85>) is insufficient. Companies should run an extended stability-indicating endotoxin recovery study. The primary goal of TR-82 is to provide

The TR 82 Protocol Skeleton:

PDA Technical Report 82 presents focused research and practical findings on programmable device architectures (PDA). Below is a concise, engaging post-ready summary you can share on social media, a newsletter, or a blog. The report focuses on parenteral drug products (solutions,

The Challenge: Pharmaceutical water systems (Purified Water, Water for Injection) require routine sanitization to control biofilm and microbial proliferation. The industry standard for thermal sanitization typically involves heating the water to 80°C or higher and circulating it at high velocities (turbulent flow, Reynolds number > 10,000) to ensure uniform temperature distribution and heat penetration to all wetted surfaces.

However, older facilities or systems with design limitations (e.g., pump cavitation issues at low flow, dead legs, or undersized pumps) may not be able to achieve or sustain these high flow rates during thermal treatment. Historically, regulators viewed low-flow sanitization with skepticism due to concerns about "cold spots" where bacteria could survive.

The Solution: TR 82 bridges the gap between engineering theory and practical reality. It acknowledges that while high-velocity turbulent flow is preferred, effective thermal sanitization is still achievable at lower velocities if specific temperature mapping and validation protocols are followed.

TR 82 explicitly states what regulators will ask during an inspection: